Consensus Geron Corporation

Stocks

GERN

US3741631036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 09/07/2026 +04			5-day change	1st Jan Change
1.560 ^USD	+4.70%		+22.83%	+18.18%

06-08	Geron Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08:40 AM
05-13	Geron Corporation Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 04:35 PM

Evolution of the Average Target: Geron Corporation

Evolution of the Target Price: Geron Corporation

Changes in Analyst Recommendations: Geron Corporation

09277f6ccc003e2ca8190ab.tlNmqFfbyNAfJaX95c3qWyBbqId2WmwMa4U4Cr_prFE.0zIqwi2Pj718V8SvjpKbPXMDnMkgGx96Eetsct3E1j3xKRXiG4j-sycT1g~153c6164dff8d47a9bf2cd7e4661f932

Analysts' recommendations: Geron Corporation

11-06	Wedbush Cuts Price Target on Geron to $5 From $6, Keeps Outperform Rating	MT
08/05/25	Scotiabank Downgrades Geron to Sector Perform From Sector Outperform, Adjusts Price Target to $1.50 From $4	MT
27/02/25	B. Riley Downgrades Geron to Neutral From Buy, Cuts Price Target to $2 From $3.50	MT
26/02/25	Wedbush Lowers Geron's Price Target to $7 From $8, Outperform Rating Maintained	MT
26/02/25	HC Wainwright Downgrades Geron to Neutral From Buy	MT
18/02/25	B. Riley Adjusts Geron Price Target to $3.50 From $5.50, Maintains Buy Rating	MT
16/10/24	Scotiabank Initiates Geron at Sector Outperform With $6 Price Target	MT
09/09/24	Leerink Partners Initiates Coverage on Geron With Outperform Rating, $7 Price Target	MT
09/08/24	B. Riley Adjusts Price Target on Geron to $5.50 From $5, Maintains Buy Rating	MT
10/06/24	Barclays Initiates Geron at Overweight Rating With $9 Price Target	MT
10/06/24	Stifel Nicolaus Adjusts Geron Price Target to $7 From $6, Maintains Buy Rating	MT
07/06/24	Wedbush Raises Geron's Price Target to $8 From $7, Outperform Rating Maintained	MT
07/06/24	Needham Adjusts Geron Price Target to $6 From $5, Maintains Buy Rating	MT
03/05/24	Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating	MT
30/04/24	Baird Downgrades Geron to Neutral From Outperform, Price Target at $4.50	MT
29/04/24	TD Cowen Initiates Geron With Buy Rating, $10 Price Target	MT
15/03/24	Needham Adjusts Geron's Price Target to $5 From $4, Maintains Buy Rating	MT
15/03/24	Goldman Sachs Adjusts Price Target on Geron to $5 From $4, Keeps Buy Rating	MT
12/09/23	Goldman Sachs Upgrades Geron to Buy From Neutral, Price Target is $4	MT
28/03/23	Goldman Sachs Initiates Geron at Neutral With $3 Price Target	MT
09/01/23	Needham Adjusts Price Target on Geron to $4 From $3, Maintains Buy Rating	MT
09/01/23	B. Riley Lifts Geron's PT to $5 From $4, Keeps Buy Rating After Positive Topline Results From Phase III Trial of Imetelstat	MT
04/01/23	Wedbush Lifts Geron's Price Target to $6 From $5, Keeps Outperform Rating	MT
28/10/22	Wedbush Starts Geron at Outperform With $5 Price Target	MT
12/08/22	Needham & Co Adjusts Geron Price Target to $3 From $2, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GERON CORPORATION					+117.95%
	ARGENX SE					+10.86%
	WUXI APPTEC CO., LTD.					+27.1%
	INSMED INCORPORATED					+69.1%
	BIONTECH SE					+30.3%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.14%
	GENMAB A/S					+23.4%
	PHARMAESSENTIA CORPORATION					-23.9%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+14.23%
	EXELIXIS, INC.					-10.22%
	Average					+29.00%
	Weighted average by Cap.					+21.71%